# A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

> **NCT02206035** · PHASE2 · COMPLETED · sponsor: **William R. Drobyski, MD** · enrollment: 45 (actual)

## Conditions studied

- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02206035
- **Lead sponsor:** William R. Drobyski, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206035, "A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02206035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*